Product image of Montelucaste Krka (Montelukast) supplied by GNH India

Montelucaste Krka

Active Ingredient:
Montelukast
Origin:
EU

Montelucaste Krka (Montelukast)

Montelukast, the active ingredient in Montelucaste Krka, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis by blocking cysteinyl leukotriene receptors that contribute to airway inflammation and nasal symptoms.

GNH India supplies Montelucaste Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Manufacturer / TM Owner

Krka Farmacêutica, Unipessoal Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast acts on the leukotriene pathway to control respiratory and allergic conditions.

  • Asthma: helps control chronic symptoms and reduces exacerbations in patients with persistent asthma.
  • Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis.
  • Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after vigorous physical activity.

How It Works

  • Montelukast selectively antagonizes cysteinyl leukotriene (CysLT1) receptors located on airway smooth muscle, inflammatory cells and vascular endothelium. By blocking the binding of leukotrienes D4, E4 and F4, it inhibits bronchoconstriction, mucus secretion, vascular permeability and eosinophil recruitment, thereby reducing airway inflammation and allergic symptoms.

Side Effects

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Headache: mild to moderate intensity, often transient.
  • Abdominal pain: discomfort in the stomach area, usually self‑limiting.
  • Cough: non‑productive cough without infection.
  • Dyspepsia: indigestion or feeling of fullness.
  • Fatigue: generalized tiredness.
  • Nausea: sensation of needing to vomit.

Serious or Rare Side Effects

  • Allergic reactions: including angioedema, urticaria or anaphylaxis.
  • Neuropsychiatric events: mood changes, depression, suicidal thoughts or behavior.
  • Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.
  • Hepatic injury: elevated liver enzymes or hepatitis.

Precautions & Warnings

When prescribing Montelukast, clinicians should consider several safety precautions.

  • Assess asthma control before initiating: ensure the patient has persistent asthma that requires a controller medication.
  • Monitor for neuropsychiatric symptoms: watch for mood changes, depression, anxiety or suicidal thoughts.
  • Use caution in hepatic impairment: adjust therapy if liver function tests are abnormal.
  • Avoid in patients with known hypersensitivity to montelukast or any tablet excipients.
  • Pregnancy and lactation: discuss potential risks with the prescriber before use.
  • Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Montelukast can interact with other medicines that affect its metabolism or share similar pharmacologic effects.

Major Interactions (Avoid)

  • Ritonavir (strong CYP3A4 inhibitor): may increase montelukast plasma concentrations.
  • Ketoconazole (CYP3A4 inhibitor): may raise exposure and risk of side effects.
  • Phenobarbital (CYP inducer): may reduce montelukast effectiveness.

Moderate Interactions (Monitor Closely)

  • Fluticasone inhaler: additive effect on asthma control may require dose adjustment.
  • Zafirlukast (another leukotriene antagonist): concurrent use can increase risk of adverse reactions.
  • Warfarin: monitor INR as montelukast may alter anticoagulant metabolism.

Frequently Asked Questions

Montelucaste Krka contains montelukast, which is approved for the chronic management of asthma, relief of symptoms of allergic rhinitis, and prevention of exercise‑induced bronchoconstriction. It helps reduce airway inflammation, improve breathing, and control nasal allergy symptoms in patients who need a daily controller medication.

Montelukast selectively blocks cysteinyl leukotriene (CysLT1) receptors on airway smooth muscle and inflammatory cells. By preventing leukotrienes D4, E4 and F4 from binding, it inhibits bronchoconstriction, mucus production, vascular leakage and eosinophil recruitment, thereby decreasing airway inflammation and allergic responses.

The appropriate dose of Montelucaste Krka is set by the prescribing clinician based on the patient’s age, weight, severity of asthma or allergic rhinitis, and any co‑existing medical conditions. Dosage may differ for adults, children, and for specific indications such as exercise‑induced bronchoconstriction.

Safety data for montelukast in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against possible risks and discuss them with the patient before initiating therapy during pregnancy or while breastfeeding.

To order Montelucaste Krka, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast and inhaled corticosteroids (ICS) target different aspects of asthma. Montelukast blocks leukotriene‑mediated inflammation, while ICS suppress a broader range of inflammatory pathways. Montelukast is often used as an add‑on therapy for patients who remain symptomatic on ICS or who prefer an oral option, but it is not a substitute for high‑dose ICS in severe disease.

Montelucaste Krka should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Montelucaste Krka is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the same time each day. No food restrictions are required, but patients should follow the prescriber’s instructions regarding timing relative to meals.

The most serious risks include neuropsychiatric events such as mood changes, depression, anxiety, or suicidal thoughts, and severe allergic reactions like angioedema, anaphylaxis, or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelucaste Krka should be avoided in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, and it should be used only under medical supervision in pregnant or breastfeeding women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT